Anbio Biotechnology Class A Ordinary Shares
NNNNNASDAQHealthcare● Active
$17.22
$-5.77(-25.10%)
Market Cap$755806464
P/E Ratio—
52W High$55.65
52W Low$7.92
Anbio Biotechnology Class A Ordinary Shares (NNNN) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · NNNN · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $9.76M | $8.19M | $6.71M | $23.54M | $4.43M |
| Cost of Revenue | $1.25M | $2.30M | $3.35M | $10.98M | $1.89M |
| Gross Profit | $8.51M | $5.89M | $3.36M | $12.56M | $2.54M |
| Gross Margin %(computed) | 87.24% | 71.90% | 50.07% | 53.36% | 57.40% |
| Operating Expenses | |||||
| R&D Expenses | $0.23M | $0.45M | $0.13M | $0.20M | $0.00M |
| G&A Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Total Operating Expenses | $2.00M | $3.89M | $1.40M | $2.37M | $0.09M |
| Operating Income | $6.51M | $2.00M | $1.96M | $10.20M | $2.46M |
| Operating Margin %(computed) | 66.70% | 24.38% | 29.22% | 43.30% | 55.46% |
| Interest Income | $0.16M | $0.34M | $0.17M | $0.04M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.01M | $0.00M |
| Income Before Tax | $7.23M | $2.37M | $2.25M | $10.01M | $2.54M |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | $7.23M | $2.37M | $2.25M | $10.01M | $2.54M |
| Net Margin %(computed) | 74.06% | 28.99% | 33.58% | 42.52% | 57.26% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.16 | $0.06 | $0.02 | $0.07 | $0.03 |
| Wtd Avg Shares | 43.89M | 42.29M | 143.89M | 143.89M | 100.00M |
| EBITDA | $6.51M | $2.57M | $2.27M | $10.03M | $2.54M |
| EBITDA Margin %(computed) | 66.70% | 31.36% | 33.77% | 42.58% | 57.26% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Anbio Biotechnology Class A Ordinary Shares data
About Anbio Biotechnology Class A Ordinary Shares (NNNN) Income Statement
Anbio Biotechnology Class A Ordinary Shares (NNNN) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, NNNN reported revenue of $0.01B, gross profit of $0.01B (gross margin 87.24%), and net income of $0.01B — a net profit margin of 74.06%.
Frequently asked questions
NNNN · 4 questionsAnbio Biotechnology Class A Ordinary Shares (NNNN) reported revenue of $0.01B for 2025, up 19.2% year-over-year.
NNNN revenueNNNN salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08